General Information of Drug Therapeutic Target (DTT) (ID: TTPNQAC)

DTT Name Estrogen-related receptor-alpha (ESRRA)
Synonyms
Nuclear receptor subfamily 3 group B member 1; NR3B1; Estrogen-relatedreceptor, alpha; Estrogen-relatedreceptor alpha; Estrogen-related receptor alpha; Estrogen receptor-like 1; ESRL1; ERRalpha; ERR1; ERR-alpha
Gene Name ESRRA
DTT Type
Successful target
[1]
BioChemical Class
Nuclear hormone receptor
UniProt ID
ERR1_HUMAN
TTD ID
T72841
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MSSQVVGIEPLYIKAEPASPDSPKGSSETETEPPVALAPGPAPTRCLPGHKEEEDGEGAG
PGEQGGGKLVLSSLPKRLCLVCGDVASGYHYGVASCEACKAFFKRTIQGSIEYSCPASNE
CEITKRRRKACQACRFTKCLRVGMLKEGVRLDRVRGGRQKYKRRPEVDPLPFPGPFPAGP
LAVAGGPRKTAAPVNALVSHLLVVEPEKLYAMPDPAGPDGHLPAVATLCDLFDREIVVTI
SWAKSIPGFSSLSLSDQMSVLQSVWMEVLVLGVAQRSLPLQDELAFAEDLVLDEEGARAA
GLGELGAALLQLVRRLQALRLEREEYVLLKALALANSDSVHIEDAEAVEQLREALHEALL
EYEAGRAGPGGGAERRRAGRLLLTLPLLRQTAGKVLAHFYGVKLEGKVPMHKLFLEMLEA
MMD
Function
Can bind to the medium-chain acyl coenzyme A dehydrogenase (MCAD) response element NRRE-1 and may act as an important regulator of MCAD promoter. Binds to the C1 region of the lactoferrin gene promoter. Requires dimerization and the coactivator, PGC-1A, for full activity. The ERRalpha/PGC1alpha complex is a regulator of energy metabolism. Induces the expression of PERM1 in the skeletal muscle. Binds to an ERR-alpha response element (ERRE) containing a single consensus half-site, 5'-TNAAGGTCA-3'.
Reactome Pathway
Transcriptional activation of mitochondrial biogenesis (R-HSA-2151201 )
Nuclear Receptor transcription pathway (R-HSA-383280 )
PPARA activates gene expression (R-HSA-1989781 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
2 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Rimexolone DMTAREC Arthritis FA20 Approved [1]
Pregnenolone DM6VFO1 Schizophrenia 6A20 Phase 4 [2]
------------------------------------------------------------------------------------
2 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
D-5519 DM9FAJM Asthma CA23 Phase 3 [3]
Dexamethasone palmitate DMCMT4V Choroidal neovascularization 9B76 Phase 1/2 [4]
------------------------------------------------------------------------------------
6 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Rofleponide DM6OSPQ Allergic rhinitis CA08.0 Discontinued in Phase 2 [5]
RPR-106541 DMRGC5B Asthma CA23 Discontinued in Phase 2 [6]
AD-121 DMB8XJM Rheumatoid arthritis FA20 Discontinued in Phase 1/2 [1]
GW-250495 DMWJZAP Asthma CA23 Discontinued in Phase 1 [1]
PLD-177 DMPHUBO Allergic rhinitis CA08.0 Terminated [1]
Steroid hormone conjugates DMOJM08 Cachexia MG20 Terminated [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Discontinued Drug(s)
18 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
2-(4-Hydroxy-phenyl)-4-vinyl-quinolin-6-ol DM81G2U Discovery agent N.A. Investigative [8]
4-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol DMPSRAC Discovery agent N.A. Investigative [8]
4-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol DMKJ18X Discovery agent N.A. Investigative [8]
4-Ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol DMTIY89 Discovery agent N.A. Investigative [8]
4-Ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol DMXLZAT Discovery agent N.A. Investigative [8]
7-bromo-6H-chromeno[4,3-b]quinoline-3,9-diol DMX85IF Discovery agent N.A. Investigative [8]
7-chloro-6H-chromeno[4,3-b]quinoline-3,9-diol DMRNZYQ Discovery agent N.A. Investigative [8]
7-ethyl-6H-chromeno[4,3-b]quinoline-3,9-diol DMSFODU Discovery agent N.A. Investigative [8]
7-ethynyl-6H-chromeno[4,3-b]quinoline-3,9-diol DMJWCAH Discovery agent N.A. Investigative [8]
7-vinyl-6H-chromeno[4,3-b]quinoline-3,9-diol DM14OHR Discovery agent N.A. Investigative [8]
biochanin A DM0HPWY Discovery agent N.A. Investigative [9]
chlordane DMMHU8G Discovery agent N.A. Investigative [10]
daidzein DMRFTJX Discovery agent N.A. Investigative [9]
NCX-1047 DM1FOSP Dermatitis EA80-EA89 Investigative [1]
PMID17556356C1a DM7Z2WV Discovery agent N.A. Investigative [11]
TDT-044 DMRU8WT Dermatological disease DA24.Y Investigative [1]
toxaphene DM4R657 Discovery agent N.A. Investigative [10]
XCT790 DMZ7N8D Discovery agent N.A. Investigative [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 18 Investigative Drug(s)

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Asthma CA23 Nasal and bronchial airway 2.85E-08 0.26 0.47
Schizophrenia 6A20 Pre-frontal cortex 9.34E-01 1.47E-02 0.06
Schizophrenia 6A20 Superior temporal cortex 2.09E-01 -0.07 -0.62
Rheumatoid arthritis FA20 Synovial tissue 3.46E-01 0.06 0.14
Atopic dermatitis EA90 Skin 6.95E-14 0.51 3.32
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 622).
2 Suppression of adrenal function by low-dose prednisone: assessment with 24-hour urinary steroid hormone profiles--a review of five cases. Altern Med Rev. 2006 Mar;11(1):40-6.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007199)
4 Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial. Lancet. 2002 Jul 20;360(9328):211-8.
5 Direct activation of GABAA receptors by loreclezole, an anticonvulsant drug with selectivity for the beta-subunit. Neuropharmacology. 1996;35(12):1753-60.
6 Use of the steroid derivative RPR 106541 in combination with site-directed mutagenesis for enhanced cytochrome P-450 3A4 structure/function analysis. J Pharmacol Exp Ther. 1999 Aug;290(2):594-602.
7 The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf). 1998 Oct;49(4):421-32.
8 ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4053-6.
9 Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res. 2003 Nov;1(13):981-91.
10 Two organochlorine pesticides, toxaphene and chlordane, are antagonists for estrogen-related receptor alpha-1 orphan receptor. Cancer Res. 1999 Sep 15;59(18):4519-24.
11 Crystal structure of human estrogen-related receptor alpha in complex with a synthetic inverse agonist reveals its novel molecular mechanism. J Biol Chem. 2007 Aug 10;282(32):23231-9.
12 Regulation of PPARgamma coactivator 1alpha (PGC-1alpha) signaling by an estrogen-related receptor alpha (ERRalpha) ligand. Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):8912-7.